Semiconductor Metrology and Inspection Leader Jiangling Technology Closes Two Consecutive Rounds Worth Hundreds of Millions of Yuan, with Qiming Venture Partners Leading B+ Round

Jiangling Technology, a leading domestic semiconductor metrology and inspection equipment company, recently announced the successful completion of its Series B and B+ funding rounds, with Qiming Venture Partners leading the B+ round. The proceeds will be primarily used for new product development and scaling up production capacity.

Founded in 2018, Jiangling Technology is dedicated to providing advanced optical metrology and inspection equipment for global semiconductor customers, with the goal of becoming a top-tier semiconductor metrology and inspection equipment company in Asia. Through years of deep engagement in this high technical-barrier field and continuous innovation, the company has successfully developed multiple advanced metrology and inspection equipment products through independent innovation, filling domestic technology gaps in this sector.

In front-end process control, Critical Thin Film Thickness measurement and Optical Critical Dimension (OCD) measurement present extremely high systemic technical barriers. The ever-evolving process platforms demand higher performance from metrology equipment, making independent innovation in advanced metrology tools increasingly urgent.

Jiangling Technology has long focused on advanced front-end semiconductor metrology. Through sustained technology accumulation and solid customer partnerships, its core products — the critical thin film thickness measurement tool and optical critical dimension measurement tool — have already enabled stable mass production for domestic customers.

At the same time, Jiangling Technology has systematically integrated multiple AI-enabled technologies, employing physics-informed self-supervised adaptive large-scale neural network architectures, combined with machine learning methods for data preprocessing, dimensionality reduction, classification, and prediction. Using independently controllable high-performance parallel computing nodes, the company optimizes measurement precision and tool matching, advances AI model data analysis and processing capabilities, and enhances systematic learning — all to accelerate yield management and control for domestically scarce processes.

Building on its solid R&D capabilities in metrology and inspection systems, Jiangling Technology has deeply empowered multiple domains with a rich product portfolio, having successively completed the industrial adoption and batch validation of more than ten types of metrology and inspection equipment.

Jiangling Technology has accumulated dozens of core invention patents supporting its main business and continues to increase R&D investment. In 2024, its Lingang R&D headquarters closely collaborated with the National Integrated Circuit Innovation Center to jointly establish the "Semiconductor Advanced Metrology and Inspection Equipment Joint Engineering Center," strengthening industry-academia-research partnerships to accelerate solutions for persistent metrology and inspection pain points in domestically scarce processes, and to speed the development and deployment of multiple first-of-kind products urgently needed by the industry.

Meanwhile, to meet growing orders and expansion needs, Jiangling Technology's Phase II production base has begun construction and will officially commence operations in Q3 2025.

In recent years, Jiangling Technology has maintained rapid business growth, with revenue compound annual growth exceeding 200% over the past three years, while maintaining high R&D intensity with annual R&D investment exceeding 50% of revenue.

The Series B round was led by ShiXi Capital, with Hefei Industry Investment and Jucheng Capital as co-investors. The Series B+ round was led by Qiming Venture Partners, with Yuanhe Puhua, Hundun Investment, Chaoyue Capital, Lingang Digital Technology Fund, Hengqin Hanrui, and Kaifeng Yongxiang as co-investors. Existing shareholder Fengyuan Capital made additional investments.

Past Coverage

Qiming Viewpoint | Qiming Venture Partners' Gary Ye: Technological Innovation Drives Industrial Transformation Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including Top 5 China Best VC Firms at ChinaVenture Awards 2024 Qiming Honors | Qiming Venture Partners Ranks 5th in Zero2IPO's 2024 China VC Rankings, Among Five Awards

Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.

Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.